ArticleCancers2023

The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab.

Alicja Kuźniewska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.